Desnoyers A - Search Results

1

Evolution in the risk of adverse events of adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer.

Reinhorn D, Yerushalmi R, Moore A, Desnoyers A, Saleh RR, Amir E, Goldvaser H. Reinhorn D, et al. Among authors: desnoyers a. Breast Cancer Res Treat. 2020 Jul;182(2):259-266. doi: 10.1007/s10549-020-05715-1. Epub 2020 Jun 1. Breast Cancer Res Treat. 2020. PMID: 32488391 Review.

2

The Effect of Exercise on Quality of Life, Fatigue, Physical Function, and Safety in Advanced Solid Tumor Cancers: A Meta-analysis of Randomized Control Trials.

Nadler MB, Desnoyers A, Langelier DM, Amir E. Nadler MB, et al. Among authors: desnoyers a. J Pain Symptom Manage. 2019 Nov;58(5):899-908.e7. doi: 10.1016/j.jpainsymman.2019.07.005. Epub 2019 Jul 15. J Pain Symptom Manage. 2019. PMID: 31319105 Free article. Review.

3

A critique of the fragility index.

Desnoyers A, Nadler MB, Wilson BE, Amir E. Desnoyers A, et al. Lancet Oncol. 2019 Oct;20(10):e552. doi: 10.1016/S1470-2045(19)30583-2. Epub 2019 Sep 30. Lancet Oncol. 2019. PMID: 31578994 No abstract available.

4

Integrin ανβ6 Protein Expression and Prognosis in Solid Tumors: A Meta-Analysis.

Desnoyers A, González C, Pérez-Segura P, Pandiella A, Amir E, Ocaña A. Desnoyers A, et al. Mol Diagn Ther. 2020 Apr;24(2):143-151. doi: 10.1007/s40291-020-00450-1. Mol Diagn Ther. 2020. PMID: 32100239 Review.

5

Influence of Competing Risks on Estimates of Recurrence Risk and Breast Cancer-specific Mortality in Analyses of the Early Breast Cancer Trialists Collaborative Group.

Saleh RR, Nadler MB, Desnoyers A, Rodin DL, Abdel-Qadir H, Amir E. Saleh RR, et al. Among authors: desnoyers a. Sci Rep. 2020 Mar 5;10(1):4091. doi: 10.1038/s41598-020-61093-0. Sci Rep. 2020. PMID: 32139756 Free PMC article.

6

Comparison of treatment-related adverse events of different Cyclin-dependent kinase 4/6 inhibitors in metastatic breast cancer: A network meta-analysis.

Desnoyers A, Nadler MB, Kumar V, Saleh R, Amir E. Desnoyers A, et al. Cancer Treat Rev. 2020 Nov;90:102086. doi: 10.1016/j.ctrv.2020.102086. Epub 2020 Aug 17. Cancer Treat Rev. 2020. PMID: 32861975

7

Fragility index of trials supporting approval of anti-cancer drugs in common solid tumours.

Desnoyers A, Wilson BE, Nadler MB, Amir E. Desnoyers A, et al. Cancer Treat Rev. 2021 Mar;94:102167. doi: 10.1016/j.ctrv.2021.102167. Epub 2021 Feb 16. Cancer Treat Rev. 2021. PMID: 33652263 Review.

8

Network Meta-analysis Comparing Efficacy, Safety and Tolerability of Anti-PD-1/PD-L1 Antibodies in Solid Cancers.

Al-Showbaki L, Nadler MB, Desnoyers A, Almugbel FA, Cescon DW, Amir E. Al-Showbaki L, et al. Among authors: desnoyers a. J Cancer. 2021 May 19;12(14):4372-4378. doi: 10.7150/jca.57413. eCollection 2021. J Cancer. 2021. PMID: 34093837 Free PMC article.

9

Adjuvant Zoledronate Therapy for Women With Breast Cancer-Effective Treatment or Fool's Gold?

Desnoyers A, Amir E, Tannock IF. Desnoyers A, et al. JAMA Oncol. 2021 Aug 1;7(8):1121-1123. doi: 10.1001/jamaoncol.2021.1516. JAMA Oncol. 2021. PMID: 34165515 No abstract available.

10

Fragility of randomized trials supporting cancer drug approvals stratified by approval pathway and review designations.

Wilson BE, Desnoyers A, Nadler MB, Tibau A, Amir E. Wilson BE, et al. Among authors: desnoyers a. Cancer Med. 2021 Aug;10(16):5405-5414. doi: 10.1002/cam4.4029. Epub 2021 Jul 28. Cancer Med. 2021. PMID: 34323019 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

27 results

Search Page

Filters